Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome.
about
Signal transduction inhibitors in treatment of myelodysplastic syndromesOxidative stress, redox regulation and diseases of cellular differentiation.Pleiotropic functions of glutathione S-transferase PThe genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes.Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.
P2860
Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome.
@ast
Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome.
@en
type
label
Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome.
@ast
Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome.
@en
altLabel
Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome
@en
prefLabel
Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome.
@ast
Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome.
@en
P2093
P2860
P356
P1476
Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome.
@en
P2093
Gail Brown
Margarita R Brooks
Naomi Galili
Olga B Botvinnik
Pablo Tamayo
P2860
P2888
P356
10.1186/1756-8722-5-20
P407
P577
2012-05-06T00:00:00Z
P5875
P6179
1025756768